Nkarta, Inc. (NKTX)
Develops natural killer cell therapies to treat cancer and autoimmune diseases.
$2.24-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+5.7%
The outlook
NKTX is trading well below its 50- and 200-day moving averages, positioned near the lower end of its 52-week range. Analyst sentiment is mixed, with an average price target suggesting significant upside from current levels. Overall market positioning leans bearish despite the gap between current price and analyst targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range27% of the way from its 52-week low to high
Price targetAvg target +406% vs current price
Analyst price target
~12-month · 6 analysts$11.33average target+406.0% vs now
Now $2.24
Low $9.00High $16.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$160.3M
52-wk high
$3.72
52-wk low
$1.70
50-day avg
$2.81
200-day avg
$2.39
Trailing P/E
—